Detalles de la búsqueda
1.
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
Am J Gastroenterol
; 117(8): 1279-1287, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35467558
2.
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.
Int J Mol Sci
; 19(8)2018 Jul 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30060508
3.
Clinical use of biologics for Crohn's disease in adults: lessons learned from real-world studies.
Expert Opin Biol Ther
; 24(3): 171-189, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38321868
4.
Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.
J Clin Med
; 13(5)2024 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38592377
5.
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Expert Opin Biol Ther
; 24(1-2): 101-109, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38250818
6.
Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists.
J Clin Med
; 12(5)2023 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36902792
7.
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Inflamm Bowel Dis
; 29(3): 376-383, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35579320
8.
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Expert Opin Biol Ther
; 23(3): 293-304, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36843568
9.
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Expert Opin Pharmacother
; 24(14): 1649-1656, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358928
10.
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Biomedicines
; 10(8)2022 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35892698
11.
Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study.
World J Clin Cases
; 10(30): 10921-10930, 2022 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36338227
12.
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study.
Biomedicines
; 10(4)2022 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35453593
13.
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Expert Opin Biol Ther
; 22(2): 313-320, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34904510
14.
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
J Gastrointestin Liver Dis
; 31(4): 411-416, 2022 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36535057
15.
Review article: safety of new biologic agents for inflammatory bowel disease in the liver.
Eur J Gastroenterol Hepatol
; 33(5): 623-630, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33470695
16.
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study.
United European Gastroenterol J
; 9(4): 507-516, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33259773
17.
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
J Gastrointestin Liver Dis
; 30(4): 456-461, 2021 12 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34812437
18.
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Eur J Gastroenterol Hepatol
; 33(5): 670-679, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33741797
19.
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
United European Gastroenterol J
; 9(1): 102-109, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33203342
20.
Use of infliximab in particular clinical settings: management based on current evidence.
Am J Gastroenterol
; 104(6): 1575-86, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19491875